Skip to main
DBD
DBD logo

DBD Stock Forecast & Price Target

DBD Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Diebold Nixdorf Inc. reported a 8.1% quarter-over-quarter and 7.8% year-over-year growth in Retail revenues, totaling $255 million, alongside a notable expansion of gross margins by 100 basis points to 24.7%. The company is set to achieve a significant increase in free cash flow (FCF), with an expected rise to $205 million in 2025, compared to $109 million in 2024; Q3 2025 marked the first time it generated positive FCF for four consecutive quarters. Additionally, the robust growth in revenue is anticipated to contribute to notable year-over-year earnings per share (EPS) growth in 2026, along with targeted gross margin improvements that could enhance overall profitability.

Bears say

Diebold Nixdorf faces significant challenges that contribute to a negative outlook on its stock, primarily stemming from technological missteps and a failure to innovate, which could adversely impact both revenues and profitability. The company's Banking segment has exhibited declining gross margins, with a recent total of 26.8%, which reflects increased competitive pressures and potential difficulties in meeting its debt obligations. Additionally, uncertainties in the global trade environment, disruptions in supply chains, and lower-than-anticipated demand for upgrades and replacements further exacerbate the company's financial vulnerabilities.

DBD has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Diebold Nixdorf Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Diebold Nixdorf Inc (DBD) Forecast

Analysts have given DBD a Buy based on their latest research and market trends.

According to 2 analysts, DBD has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Diebold Nixdorf Inc (DBD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.